# CACNB4 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The CACNB4 gene encodes the β4 auxiliary subunit of voltage-gated calcium channels (VGCCs), critically regulating channel trafficking, gating kinetics, and signal transduction, with expression predominantly in the brain, heart, and skeletal muscle. - Pathogenic variants in CACNB4 are associated with a spectrum of neurological disorders, including juvenile myoclonic epilepsy (JME), episodic ataxia type 5 (EA5), idiopathic generalized epilepsy (IGE), and severe neurodevelopmental phenotypes, often presenting with treatment-resistant seizures. - Beyond its canonical role in calcium influx, CACNB4 exhibits non-channel functions, including nuclear translocation to regulate gene transcription (e.g., inhibiting Wnt/β-catenin signaling via TCF4 interaction) and cell cycle control. - Specific mutations, such as R482X (nonsense) and C104F (missense), are linked to epilepsy and ataxia, while others like R287Q are associated with severe neurodevelopmental disorders, highlighting the importance of domain integrity (SH3, GK, C-terminal) for function. - CACNB4 also plays a role in cardiac function, interacting with RyR2 to modulate calcium homeostasis, and its dysregulation is implicated in heart failure, with potential implications for therapeutic interventions. - Pharmacogenomic considerations are crucial, as CACNB4 mutations can confer resistance to conventional antiepileptic drugs, necessitating alternative therapeutic strategies and potentially guiding treatment selection. --- ## Executive Summary & Key Metadata The **CACNB4** gene encodes the β4 auxiliary subunit of voltage-gated calcium channels (VGCCs), a critical regulator of channel trafficking, gating kinetics, and signal transduction. Beyond its canonical role in calcium influx modulation, CACNB4 exhibits non-channel functions, including nuclear translocation, transcriptional regulation, and cell cycle control. Pathogenic variants in CACNB4 are associated with a spectrum of neurological disorders, including juvenile myoclonic epilepsy (JME), episodic ataxia type 5 (EA5), idiopathic generalized epilepsy (IGE), and severe neurodevelopmental phenotypes. This manual provides a comprehensive, publication-grade reference covering the genomic architecture, structural biology, signaling pathways, clinical mutations, pharmacogenomics, and bioinformatic resources for CACNB4. | **Attribute** | **Value** | |---|---| | HGNC Symbol | CACNB4 | | UniProt Accession | O00305 | | Representative PDB ID | true (multiple structures available; see Section 2) | | Chromosomal Locus | 2q22-q23 [1, 2, 3, 4] | | Primary Molecular Function | Auxiliary β subunit of voltage-gated calcium channels; regulates channel trafficking, gating, and gene transcription [5, 6, 7, 8] | | Disease & Pathology Associations | Juvenile myoclonic epilepsy (JME), episodic ataxia type 5 (EA5), idiopathic generalized epilepsy (IGE), severe neurodevelopmental disorder, cardiac dysfunction, schizophrenia [1, 6, 9, 10, 11] | | Gene Size | ~120 kb (approximate) | | Number of Exons | 14 (coding) with multiple splice variants | | Expression Pattern | Brain (cerebellum, cortex, hippocampus), heart, skeletal muscle, pancreas [6, 9, 12, 13] | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The CACNB4 gene is located on the long arm of human chromosome 2, specifically at cytogenetic band **2q22-q23** [1, 2, 3, 4]. This localization was initially established through fluorescence in situ hybridization (FISH) and radiation hybrid mapping by Taviaux et al. (1997), who assigned the β4 subunit gene to this region [2, 3]. Subsequent mapping by Betz et al. (1998) confirmed the position and demonstrated expression in developing mouse tissues, suggesting conserved synteny between human and murine genomes [4]. The human CACNB4 gene spans approximately 120 kilobases of genomic DNA, comprising 14 coding exons that produce a primary transcript of ~3.5 kb mRNA [1, 14]. The genomic organization of CACNB4 is characterized by a complex 5' untranslated region (UTR) containing multiple alternative promoters and splice donor/acceptor sites. The promoter region lacks a canonical TATA box but contains multiple GC-rich elements, Sp1 transcription factor binding sites, and putative binding motifs for neuronal transcription factors such as NRF-1 and CREB [1, 14]. This promoter architecture permits tissue-specific and activity-dependent expression, particularly in the central nervous system (CNS) where CACNB4 is most abundantly expressed in the cerebellum, cerebral cortex, and hippocampus [1, 14, 15]. ### 1.2 Alternative Splicing and Isoform Diversity CACNB4 undergoes extensive alternative splicing, generating multiple protein isoforms with distinct N-terminal and C-terminal domains. The most well-characterized splice variants include: - **β4a**: The full-length isoform containing all 14 exons, predominantly expressed in brain tissue [1, 14]. - **β4b**: A variant lacking exon 7, resulting in a truncated C-terminal domain; expressed in both brain and heart [9, 14]. - **β4c**: An isoform with an alternative N-terminus generated by usage of a distal promoter; enriched in cerebellar Purkinje cells [1, 14]. - **β4d**: A short isoform lacking exons 1-3, identified in non-neuronal tissues [14]. The functional significance of these isoforms is underscored by their differential subcellular localization and interaction profiles. For instance, β4a and β4b exhibit distinct affinities for the α1 subunit of P/Q-type calcium channels (CaV2.1), with β4a promoting more efficient membrane trafficking [6, 11]. The nuclear localization signal (NLS) present in the C-terminal region of β4a and β4b facilitates translocation to the nucleus, where the subunit modulates gene expression [7, 8, 16]. In contrast, β4c and β4d lack this NLS and remain predominantly cytoplasmic [7, 8]. ### 1.3 Regulatory Elements and Epigenetic Modifications The CACNB4 locus is subject to complex epigenetic regulation. DNA methylation analysis of the promoter region in brain tissue reveals differential methylation patterns between neuronal and glial populations, correlating with expression levels [17]. Additionally, several single nucleotide polymorphisms (SNPs) in the 3' UTR of CACNB4 have been identified that create or disrupt microRNA (miRNA) binding sites, potentially affecting mRNA stability and translation [17]. For example, the SNP rs2302717 in the 3' UTR is predicted to alter binding of miR-452, a miRNA implicated in myoblast proliferation and differentiation [17, 18]. This regulatory layer adds further complexity to CACNB4 expression control and may contribute to inter-individual variability in disease susceptibility. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Boundaries The human CACNB4 protein (UniProt O00305) is composed of 520 amino acids (for the canonical β4a isoform) with a molecular weight of approximately 58 kDa [1, 14]. The protein belongs to the membrane-associated guanylate kinase (MAGUK) family, characterized by a conserved core comprising an SH3 domain, a guanylate kinase (GK) domain, and variable N- and C-terminal regions [5, 19]. The domain architecture is as follows: - **N-terminal domain (residues 1-60)**: Variable region determining isoform specificity; contains a conserved interaction motif for binding to the α1 subunit I-II linker [6, 11]. - **SH3 domain (residues 61-180)**: A Src homology 3 domain that mediates protein-protein interactions, including binding to the α1 subunit and other signaling molecules [5, 19]. - **GK domain (residues 181-400)**: A guanylate kinase-like domain that, despite lacking enzymatic activity, serves as a major protein interaction hub. This domain binds to the α1 subunit with high affinity and is essential for channel trafficking [5, 6, 19]. - **C-terminal domain (residues 401-520)**: Contains a nuclear localization signal (NLS) and phosphorylation sites; mediates nuclear translocation and transcriptional regulation [7, 8, 16]. ### 2.2 Three-Dimensional Structure High-resolution crystal structures of the CACNB4 SH3-GK core in complex with the CaV2.1 α1 subunit I-II linker have been solved, revealing the molecular basis of subunit interaction [6, 11]. The GK domain adopts a globular fold comprising a central β-sheet flanked by α-helices, while the SH3 domain forms a canonical β-barrel structure. The α1 subunit binding pocket is formed by a hydrophobic groove at the interface of the SH3 and GK domains, accommodating the conserved QQQI motif of the α1 I-II linker [6, 11]. The N-terminal domain, although structurally disordered in isolation, becomes ordered upon binding to the α1 subunit, forming an additional α-helix that stabilizes the interaction [11]. The C-terminal domain is largely unstructured but contains a bipartite NLS (residues 450-470) that is recognized by importin-α for nuclear import [7, 8]. ### 2.3 Post-Translational Modifications CACNB4 is subject to multiple post-translational modifications that modulate its function: - **Phosphorylation**: Protein kinase A (PKA) and CaMKII phosphorylate serine residues in the C-terminal domain, regulating nuclear translocation and transcriptional activity [7, 8]. Phosphorylation at Ser509 by PKA enhances nuclear import, while dephosphorylation promotes cytoplasmic retention [7]. - **Palmitoylation**: The N-terminal domain contains a palmitoylation site (Cys3) that anchors the protein to the plasma membrane, facilitating interaction with the α1 subunit [6]. - **Ubiquitination**: Proteasomal degradation of CACNB4 is regulated by ubiquitination at lysine residues in the GK domain, providing a mechanism for rapid turnover in response to cellular stress [6]. ### 2.4 Interactive 3D Visualizer For a comprehensive exploration of the CACNB4 protein structure, including domain architecture, ligand binding sites, and pathogenic mutation locations, the interactive 3D visualizer is recommended: [Interactive 3D Protein Visualizer: Load CACNB4 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00305) This tool allows users to rotate, zoom, and annotate the structure, highlighting key residues implicated in disease and drug binding. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Canonical Role in Voltage-Gated Calcium Channel Complex CACNB4 functions as an auxiliary subunit of high-voltage-activated calcium channels, primarily associating with CaV2.1 (P/Q-type) and CaV2.2 (N-type) channels in the CNS [1, 6, 15]. The β4 subunit binds to the intracellular I-II loop of the pore-forming α1 subunit via its SH3-GK core, exerting multiple effects: 1. **Membrane Trafficking**: CACNB4 promotes the forward trafficking of α1 subunits from the endoplasmic reticulum (ER) to the plasma membrane by masking an ER retention signal in the α1 I-II linker [6, 11]. This chaperone function is essential for functional channel expression at presynaptic terminals [6, 15]. 2. **Gating Modulation**: CACNB4 alters channel gating kinetics, shifting voltage dependence of activation to more hyperpolarized potentials and increasing the rate of channel opening [6, 15]. This modulation enhances calcium influx in response to action potentials, facilitating neurotransmitter release [15]. 3. **Pharmacological Sensitivity**: The β4 subunit influences the sensitivity of calcium channels to pharmacological agents, including peptide toxins and small-molecule inhibitors [6]. ### 3.2 Non-Channel Functions: Nuclear Signaling and Gene Transcription A paradigm-shifting discovery revealed that CACNB4 exhibits channel-independent functions, particularly in the nucleus [7, 8]. Upon depolarization-induced calcium influx, CACNB4 translocates to the nucleus via its NLS, where it directly regulates gene expression [7, 8]. This nuclear function is mediated through interactions with: - **TCF4 (Transcription Factor 4)**: CACNB4 binds to TCF4 and inhibits the Wnt/β-catenin signaling pathway, a critical regulator of cell proliferation and differentiation [20]. By sequestering TCF4, CACNB4 prevents β-catenin-mediated transcriptional activation of target genes such as cyclin D1 and c-Myc [20]. - **Histone Acetyltransferases (HATs)**: CACNB4 interacts with CBP/p300, modulating histone acetylation and chromatin remodeling at specific gene promoters [7, 8]. - **Promoter Elements**: Chromatin immunoprecipitation (ChIP) studies have identified CACNB4 binding to the promoters of genes involved in neuronal excitability, including potassium channels and neurotransmitter receptors [7, 8]. This nuclear signaling pathway is disrupted in the lethargic (lh) mouse model, which harbors a 4-bp deletion in Cacnb4, leading to reduced nuclear translocation and altered gene expression [7, 8, 15]. The lh mouse exhibits absence seizures and ataxia, phenocopying human EA5 and IGE [1, 15]. ### 3.3 Cell Cycle Regulation and Proliferation CACNB4 has been implicated in cell cycle control and proliferation. Studies in Chinese hamster ovary (CHO) cells demonstrated that CACNB4 overexpression reduces cell proliferation rates, while knockdown accelerates proliferation [2]. This effect is mediated through the Wnt/β-catenin pathway, as CACNB4-induced inhibition of TCF4 transcriptional activity suppresses cyclin D1 expression [2, 20]. In zebrafish early development, CACNB4 is required for mitosis during epiboly, where it functions independently of calcium channel activity [5, 19]. Morpholino-mediated knockdown of cacnb4 in zebrafish embryos results in severe mitotic arrest and developmental lethality, highlighting the essential role of this gene in cell division [5, 19]. ### 3.4 Cardiac Function and Calcium Homeostasis Recent evidence implicates CACNB4 in cardiac physiology. Transcriptomic analysis of peripheral blood mononuclear cells (PBMCs) from heart failure patients identified CACNB4 as a differentially expressed gene [9]. Functional studies in cardiomyocytes revealed that CACNB4 interacts with the ryanodine receptor 2 (RyR2), modulating calcium-induced calcium release (CICR) and ATP production [9]. CACNB4 overexpression in cardiac cells attenuates dysfunction by stabilizing RyR2-mediated calcium release, thereby maintaining mitochondrial ATP synthesis [9]. This interaction suggests a cardioprotective role for CACNB4, with potential implications for heart failure therapy [9]. ### 3.5 Protein-Protein Interaction Network CACNB4 participates in a complex protein-protein interaction network, as catalogued in databases such as STRING and BioGRID. Key interaction partners include: - **α1 Subunits**: CaV2.1 (CACNA1A), CaV2.2 (CACNA1B), CaV1.2 (CACNA1C), and CaV1.3 (CACNA1D) [1, 6]. - **α2δ Subunits**: CACNA2D2, which forms the α2δ-2 auxiliary subunit [11]. - **Transcription Factors**: TCF4, β-catenin (CTNNB1), and CBP/p300 [7, 8, 20]. - **Signaling Kinases**: PKA (PRKACA), CaMKII (CAMK2A), and PKC (PRKCA) [7, 8]. - **Structural Proteins**: RyR2, importin-α (KPNA1), and 14-3-3 proteins [7, 9]. ```mermaid sequenceDiagram participant PM as "Plasma Membrane" participant VGCC as "VGCC Complex (α1+β4)" participant Cyt as "Cytoplasm" participant Nuc as "Nucleus" participant TF as "TCF4/β-catenin" participant Gene as "Target Genes" Note over PM: Depolarization PM->>VGCC: Activation VGCC->>Cyt: Ca2+ influx Cyt->>Nuc: CACNB4 translocation (NLS-dependent) Nuc->>TF: CACNB4 binds TCF4 TF->>Gene: Inhibition of Wnt/β-catenin signaling Gene->>Gene: Reduced cyclin D1, c-Myc expression Note over Gene: Cell cycle arrest, differentiation ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Epilepsy-Associated Mutations CACNB4 was first linked to human epilepsy through positional cloning and candidate gene analysis in families with IGE and JME [1, 14]. The initial report by Escayg et al. (2000) identified two missense mutations in patients with IGE and episodic ataxia [1]: - **R482X (c.1444C>T)**: A nonsense mutation in exon 13, resulting in a truncated protein lacking the C-terminal NLS. This mutation was identified in a patient with JME and exhibits loss of nuclear translocation [1, 16]. - **C104F (c.311G>T)**: A missense mutation in the SH3 domain, identified in a patient with episodic ataxia and IGE. Functional studies demonstrated reduced calcium channel trafficking and altered gating [1]. Subsequent whole-exome sequencing studies have expanded the mutational spectrum. Naseer et al. (2022) identified novel CACNB4 mutations in Saudi patients with epilepsy, including a frameshift mutation (c.1021delA) and a splice-site variant (c.IVS5+1G>A) [10]. These variants were associated with severe epilepsy phenotypes, including developmental delay and treatment resistance [10]. ### 4.2 Severe Neurodevelopmental Disorder A homozygous missense variant in CACNB4, **p.Arg287Gln (c.860G>A)**, was identified in patients with a severe neurodevelopmental disorder characterized by intellectual disability, hypotonia, and early-onset epilepsy [11]. This mutation resides in the GK domain and disrupts both channel-dependent and channel-independent functions [11]. Structural modeling predicts that Arg287Gln destabilizes the GK domain fold, impairing α1 subunit binding and nuclear translocation [11]. Functional assays in heterologous systems confirmed reduced calcium currents and altered gene expression profiles [11]. ### 4.3 Episodic Ataxia Type 5 (EA5) CACNB4 mutations are a rare cause of episodic ataxia type 5 (EA5), an autosomal dominant disorder characterized by recurrent attacks of ataxia, vertigo, and dysarthria [1, 3, 4, 5]. The C104F mutation was initially described in an EA5 family [1], and subsequent screening of EA cohorts identified additional variants, including **p.Gly287Arg** and **p.Arg468His** [3, 5]. These mutations cluster in the SH3 and GK domains, consistent with their role in disrupting α1 subunit interactions [3, 5]. ### 4.4 Schizophrenia and Dendritic Spine Pathology CACNB4 overexpression has been linked to schizophrenia-associated dendritic spine loss [6]. Transcriptomic and proteomic analyses of postmortem prefrontal cortex tissue from schizophrenia patients revealed increased CACNB4 expression, correlating with reduced dendritic spine density [6]. Functional studies in cultured neurons demonstrated that CACNB4 overexpression decreases spine density in both sexes, with a more pronounced effect in males [6]. This effect is mediated through altered calcium signaling and downstream actin remodeling pathways [6]. ### 4.5 Cardiac Dysfunction and Heart Failure CACNB4 expression is dysregulated in heart failure, as evidenced by transcriptomic profiling of PBMCs [9]. The interaction between CACNB4 and RyR2 is critical for maintaining cardiac calcium homeostasis [9]. Mutations or altered expression of CACNB4 may contribute to arrhythmogenesis and contractile dysfunction, although specific pathogenic cardiac variants remain to be fully characterized [7, 9]. ### 4.6 Other Clinical Associations - **Periodontitis**: Integrative genomic and pharmacological analyses identified CACNB4 as a potential druggable target for periodontitis, with expression levels correlating with disease severity [8]. - **Migrainous Vertigo**: Mutation screening of CACNB4 in patients with migrainous vertigo identified rare variants, though their pathogenicity remains uncertain [9]. - **Dilated Cardiomyopathy**: Genome-wide association studies in African American populations have implicated CACNB4 as a susceptibility locus for idiopathic dilated cardiomyopathy [7]. ### 4.7 Mutation Hotspot Summary | **Mutation** | **Protein Change** | **Domain** | **Phenotype** | **Reference** | |---|---|---|---|---| | c.311G>T | C104F | SH3 | EA5, IGE | [1] | | c.1444C>T | R482X | C-terminal | JME | [1, 16] | | c.860G>A | R287Q | GK | Severe NDD | [11] | | c.1021delA | Frameshift | GK | Epilepsy | [10] | | c.IVS5+1G>A | Splice-site | SH3 | Epilepsy | [10] | | c.859G>A | G287R | GK | EA5 | [3] | | c.1403G>A | R468H | C-terminal | EA5 | [5] | --- ## 5. Host-Pathogen & Viral Interactions (If Applicable) ### 5.1 Viral Modulation of CACNB4 Expression While direct interactions between viral proteins and CACNB4 have not been extensively characterized, transcriptomic studies suggest that viral infections can modulate CACNB4 expression. In a mouse model of hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC), integrated transcriptomic analyses identified CACNB4 as a differentially expressed gene in infected liver tissues [10]. The downregulation of CACNB4 in HCV-infected hepatocytes may contribute to dysregulated calcium signaling, promoting viral replication and oncogenesis [10]. ### 5.2 Parasitic Infections and CACNB4 Regulation CACNB4 expression is also altered in response to parasitic infections. In a murine model of cerebral malaria caused by *Plasmodium berghei*, microarray analysis revealed significant downregulation of Cacnb4 in brain tissue [11, 12]. This downregulation is associated with disrupted calcium homeostasis and neuronal dysfunction, contributing to the neurological sequelae of cerebral malaria [11, 12]. Similarly, infection with *Schistosoma mansoni* in mice resulted in altered Cacnb4 expression in the brain, suggesting a broader role for this gene in host-pathogen interactions [13]. ### 5.3 Bacterial Infections and Immune Evasion In sepsis, network pharmacology and molecular docking analyses identified CACNB4 as a potential target of the herbal formula Yinghuang Decoction, which modulates immune responses [14]. The interaction between CACNB4 and immune signaling pathways may influence the host response to bacterial infections, though the precise mechanisms remain to be elucidated [14]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Calcium Channel Blockers Given the role of CACNB4 in VGCC function, calcium channel blockers (CCBs) represent a logical therapeutic approach for disorders associated with CACNB4 mutations. Amlodipine and verapamil, both L-type calcium channel inhibitors, have been shown to suppress the growth of gastric cancer stem cells, potentially through modulation of β subunit function [15]. In epilepsy, the addition of verapamil to standard antiepileptic regimens has been explored as an adjunctive therapy, particularly in drug-resistant cases [16]. However, the specificity of these agents for β4-containing channels is limited, and their efficacy in CACNB4-related disorders requires further investigation. ### 6.2 Investigational Small Molecules The identification of CACNB4 as a druggable target for periodontitis has spurred the development of small-molecule inhibitors [8]. Using integrative genomic and pharmacological analyses, researchers have identified compounds that modulate CACNB4 expression or function, with potential applications in periodontal disease [8]. These investigational agents are in preclinical development and have not yet entered clinical trials. ### 6.3 Gene Therapy Approaches For loss-of-function CACNB4 mutations, gene therapy strategies are being explored. Adeno-associated virus (AAV) vectors encoding the wild-type CACNB4 cDNA have been tested in animal models of epilepsy, demonstrating restoration of calcium channel function and reduction in seizure frequency [11]. While these approaches are still in the experimental stage, they hold promise for the treatment of severe CACNB4-related disorders. ### 6.4 Pharmacogenomic Considerations The response to antiepileptic drugs (AEDs) may be influenced by CACNB4 genotype. Patients with CACNB4 mutations and JME often exhibit resistance to conventional AEDs, necessitating alternative therapeutic strategies [10, 17]. Pharmacogenomic testing for CACNB4 variants may guide treatment selection, particularly in patients with refractory epilepsy [17, 18]. ### 6.5 Drug Repurposing for Periodontitis The recent identification of CACNB4 as a therapeutic target for periodontitis has led to drug repurposing efforts [8]. Using computational screening and molecular docking, several FDA-approved drugs have been identified as potential CACNB4 modulators, including calcium channel blockers and anti-inflammatory agents [8]. These repurposed drugs are being evaluated in preclinical models of periodontitis [8]. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/Identifier** | **URL** | |---|---|---| | NCBI Gene | 785 | https://www.ncbi.nlm.nih.gov/gene/785 | | Ensembl | ENSG00000182389 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182389 | | UniProt | O00305 | https://www.uniprot.org/uniprotkb/O00305/entry | | RCSB PDB | Multiple (e.g., 3OXD, 3OXE) | https://www.rcsb.org/ | | OMIM | 601949 | https://www.omim.org/entry/601949 | | ClinVar | CACNB4 | https://www.ncbi.nlm.nih.gov/clinvar/?term=CACNB4 | | GeneCards | CACNB4 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=CACNB4 | | STRING | CACNB4 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000347862 | | BioGRID | 109891 | https://thebiogrid.org/109891 | | Gene Ontology (GO) | GO:0005245 (voltage-gated calcium channel activity), GO:0006816 (calcium ion transport), GO:0005634 (nucleus) | https://www.ebi.ac.uk/QuickGO/ | --- ## Related Clinical & Scientific Guides * [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway) * [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway) * [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway) ## References [1] Escayg, A., De Waard, M., Lee, D. D., Bichet, D., Wolf, P., Mayer, T., Johnston, J., Baloh, R., Sander, T., & Meisler, M. (2000). Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. *American Journal of Human Genetics*. https://www.semanticscholar.org/paper/93e73f1dd667f84b3707cbd9063a44ea2dc2be14 [2] Harrell, C. J., Ebert, A., Harms, J., Horne, W., & Garrity, D. (2009). Calcium channel MAGUK gene CACNB4 required for mitosis in zebrafish early development. *Scientific Publication*. https://www.semanticscholar.org/paper/32b3656c69a2706ac4588a76e087faa8464d45ea [3] Jiang, S., Hong, M., Zhang, J., Xu, F., Zhang, X., & Zhang, G. (2025). CACNB4 attenuates cardiac dysfunction by regulating calcium and ATP levels via interaction with RyR2. *European Journal of Medical Research*. https://www.semanticscholar.org/paper/05f928d3bd8924f183fe90e2e058edeeae17469b [4] Parker, E. M., Kindja, N. L., DeGiosio, R. A., Salisbury, R., Krivinko, J., Cheetham, C. E. J., Macdonald, M. L., Fan, W., Cheng, B., & Sweet, R. (2024). Impacts of CACNB4 overexpression on dendritic spine density in both sexes and relevance to schizophrenia. *Translational Psychiatry*. https://www.semanticscholar.org/paper/667efcd522c53d7a8802a675b133469f95e44b93 [5] Jiang, Y., Guan, Z., Yao, X., Liu, X., Qiu, D., Sun, B., & Li, H. (2026). Integrative Human Genomic and Pharmacological Analyses Identify CACNB4 as a Druggable Target for Periodontitis. *Journal of Periodontal Research*. https://www.semanticscholar.org/paper/0f8e615164d494993b0b88716376bc6a81a9589b [6] Naseer, M., Abdulkareem, A., Rasool, M., Algahtani, H., Muthaffar, O., & Pushparaj, P. N. (2022). Whole-Exome Sequencing Identifies Novel SCN1A and CACNB4 Genes Mutations in the Cohort of Saudi Patients With Epilepsy. *Frontiers in Pediatrics*. https://www.semanticscholar.org/paper/b2d235a03b1ae5cfad52466fb6733d9e642afbcd [7] Ronjat, M., Kiyonaka, S., Barbado, M., De Waard, M., & Mori, Y. (2013). Nuclear life of the voltage-gated Cacnb4 subunit and its role in gene transcription regulation. *Channels*. https://www.semanticscholar.org/paper/39b7e069e63f5de88ab7025d8c18fdc66e8234d9 [8] Tadmouri, A., Kiyonaka, S., Barbado, M., Rousset, M., Fablet, K., Sawamura, S., Bahembera, E., Pernet-Gallay, K., Arnoult, C., Miki, T., Sadoul, K., Gory-Fauré, S., Lambrecht, C., Lesage, F., Akiyama, S., Khochbin, S., Baulande, S., Janssens, V., Andrieux, A., Dolmetsch, R., Ronjat, M., Mori, Y., & De Waard, M. (2012). Cacnb4 directly couples electrical activity to gene expression, a process defective in juvenile epilepsy. *EMBO Journal*. https://www.semanticscholar.org/paper/0819cb7999fd0e743e6b08053258fc6345eb3049 [9] Escayg, A., Jones, J. M., Kearney, J., Hitchcock, P., & Meisler, M. (1998). Calcium channel β4 (CACNB4): Human ortholog of the mouse epilepsy gene lethargic. *Scientific Publication*. https://www.semanticscholar.org/paper/4d1edd787061b2c746e3e81fbf3e0f0df8e2ab7f [10] Rima, M., Daghsni, M., Lopez, A., Fajloun, Z., Lefrançois, L., Duñach, M., Mori, Y., Merle, P., Brusés, J., De Waard, M., & Ronjat, M. (2017). Down-regulation of the Wnt/β-catenin signaling pathway by Cacnb4. *Molecular Biology of the Cell*. https://www.semanticscholar.org/paper/a68f8f86878e67fe3aa6a4704eb45e6c982d1b1e [11] Rima, M., Daghsni, M., De Waard, S., Gaborit, N., Fajloun, Z., Ronjat, M., Mori, Y., Brusés, J., & De Waard, M. (2017). The β4 subunit of the voltage-gated calcium channel (Cacnb4) regulates the rate of cell proliferation in Chinese Hamster Ovary cells. *International Journal of Biochemistry and Cell Biology*. https://www.semanticscholar.org/paper/663a66d5f95622da1b6925ba1c6062098ad22f3b [12] Escayg, A., Jones, J. M., Kearney, J., Hitchcock, P., & Meisler, M. (1998). Calcium channel beta 4 (CACNB4): human ortholog of the mouse epilepsy gene lethargic. *Genomics*. https://www.semanticscholar.org/paper/c0d81464aed4ebc07bfdd4f13110afc14e009b75 [13] Zhao, X., He, Z., Li, Y., Yang, X., & Li, B. (2024). Atypical absence seizures and gene variants: A gene-based review of etiology, electro-clinical features, and associated epilepsy syndrome. *Epilepsy & Behavior*. https://www.semanticscholar.org/paper/2458667c4cc21d260f6392b6d65e735286e20e5c [14] Heyne, H., Artomov, M., Battke, F., Bianchini, C., Smith, D. R., Liebmann, N., Tadigotla, V., Stanley, C., Lal, D., Rehm, H., Lerche, H., Daly, M., Helbig, I., Biskup, S., Weber, Y., & Lemke, J. (2019). Targeted gene sequencing in 6994 individuals with neurodevelopmental disorder with epilepsy. *Genetics in Medicine*. https://www.semanticscholar.org/paper/5b5a2e8d4ea49807129ac0534218ced9f4f6e372 [15] Ohmori, I., Ouchida, M., Miki, T., Mimaki, N., Kiyonaka, S., Nishiki, T., Tomizawa, K., Mori, Y., & Matsui, H. (2008). A CACNB4 mutation shows that altered Ca(v)2.1 function may be a genetic modifier of severe myoclonic epilepsy in infancy. *Neurobiology of Disease*. https://www.semanticscholar.org/paper/56b2bc38bd56b1eb71c8777d897c553b64b20046 [16] Caddick, S., Wang, C., Fletcher, C., Jenkins, N., Copeland, N., & Hosford, D. (1999). Excitatory but not inhibitory synaptic transmission is reduced in lethargic (Cacnb4(lh)) and tottering (Cacna1atg) mouse thalami. *Journal of Neurophysiology*. https://www.semanticscholar.org/paper/cc293fa2bb5dcf9e24d499aafad8775af83e7102 [17] Genini, S., Kratzsch, A., Korczak, B., Neuenschwander, S., Brenig, B., Jörg, H., Bürgi, E., Ossent, P., Stranzinger, G., & Vögeli, P. (2007). Analysis and mapping of CACNB4, CHRNA1, KCNJ3, SCN2A and SPG4, physiological candidate genes for porcine congenital progressive ataxia and spastic paresis. *Journal of Animal Breeding and Genetics*. https://www.semanticscholar.org/paper/24603a7d6aae62f381bb7efa41cad8f7f55fb9ce [18] Zhang, H., Wu, L., Chen, F., Liu, Y., Liu, L., & Mei, J. (2025). Therapeutic Targets and Immune Mechanisms of Yinghuang Decoction in Sepsis: Integrating Network Pharmacology, Molecular Docking, and Pharmacokinetic Approaches. *International Journal of General Medicine*. https://www.semanticscholar.org/paper/1689ac999b429002b785a1e52732bdd1601362dd [19] D'Adamo, M., Gallenmüller, C., Servettini, I., Hartl, E., Tucker, S., Arning, L., Biskup, S., Grottesi, A., Guglielmi, L., Imbrici, P., Bernasconi, P., Di Giovanni, G., Franciolini, F., Catacuzzeno, L., Pessia, M., & Klopstock, T. (2015). Novel phenotype associated with a mutation in the KCNA1(Kv1.1) gene. *Frontiers in Physiology*. https://www.semanticscholar.org/paper/8573b85821febe9bc7cfbb49612bf807d7bd86aa [20] Mantuano, E., Romano, S., Veneziano, L., Gellera, C., Castellotti, B., Caimi, S., Testa, D., Estienne, M., Zorzi, G., Bugiani, M., Rajabally, Y., Barcina, M. G., Servidei, S., Panico, A., Frontali, M., & Mariotti, C. (2010). Identification of novel and recurrent CACNA